Targeting remyelination treatment for multiple sclerosis

doi:10.5316/wjn.v5.i1.5

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14078)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

756

WORD

404

HTML

7706

Tables (1-3)

328

Sum=9194

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1064

Download

1813

Sum=2877

Publishing Process of This Article

Item

Count

Browse

870

Download

1137

Sum=2007

Mar 28, 2015 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Neurology

ISSN

2218-6212

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Neurol. Mar 28, 2015; 5(1): 5-16
Published online Mar 28, 2015. doi: 10.5316/wjn.v5.i1.5

Table 3 Repurposed drug potential for remyelination

Drug	Safety	BBB	In vitro effects	In vivo effects	MS trials	Mechanism
Quetiapine	+	+	+	+	NCT02087631	Atypical antipsychotic
Fasudil	+	NA	+	+		ROCK Inhibitor
Olesoxime	+	+	+	+	NCT01808885	Mitochondrial permeability transition pore modulator
Ibudilast	+	+	+	+	NCT01982942 NCT01910259	Phosphodiesterase PDE4 inhibitor
Simvastatin	+	+	+/-	+/-	NCT00647348	HMG-CoA reductase inhibitor
Lovastatin	+	+	+	+		HMG-CoA reductase inhibitor
Clemastine	+	+	+	+	NCT02040298	Antihistamine
IRX4204	NA	+	+	NA		Retinoid X receptor agonist
Bexarotene	+/-	+	-	-		Retinoid X receptor agonist
Benztropine	+/-	+	+	+		M1/M3 muscarinic receptor antagonist

BBB: Blood brain barrier; ROCK: Rho kinase; NA: Not available; MS: Multiple sclerosis; HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A.

Citation: Nadeem M, Sklover L, Sloane JA. Targeting remyelination treatment for multiple sclerosis. World J Neurol 2015; 5(1): 5-16
URL: https://www.wjgnet.com/2218-6212/full/v5/i1/5.htm
DOI: https://dx.doi.org/10.5316/wjn.v5.i1.5